Skip to content

FiASP vs. aspart using an advanced closed-loop system

Systems performance and glucose control using an advanced hybrid closed-loop system in type 1 diabetes: Insulin aspart vs. faster acting insulin aspart (FiASP)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12619000469112
Enrollment
24
Registered
2019-03-21
Start date
2019-06-06
Completion date
2020-03-05
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

An advanced hybrid closed-loop (A-HCL) insulin delivery system has shown safety and high time-in-range in a previous study. The use of a faster acting insulin aspart (FiASP) with a more rapid onset and shorter duration of insulin action compared to standard insulin aspart could improve the responsiveness of a HCL system. Limited data is available regarding the use of FiASP in HCL systems. The aim is to compare glucose control using A-HCL delivering FiASP vs. insulin aspart. All participants will undertake the study over a 17 week period, completing 2 study stages in random order, each of 6 week duration 1) A-HCL with FiASP, 2) A-HCL with insulin aspart. Stage 3 will be a 1 week period, reverting back to the insulin formulation used in Stage 1 without a washout period. Outcome measures include CGM time-in-range and time in hyperglycaemic and hypoglycaemic ranges; safety and system performance outcomes.

Interventions

This randomised crossover study compares glucose control using an advanced hybrid closed-loop (A-HCL) system delivering faster acting insulin aspart (FiASP) vs. insulin aspart in adults with type 1 diabetes. FiASP has a more rapid onset and shorter duration of insulin action, therefore may improve the responsive of a HCL system. There is limited data available regarding the use of FiASP in HCL systems. Participants will be assigned in random order either FiASP or insulin aspart delivery for a

This randomised crossover study compares glucose control using an advanced hybrid closed-loop (A-HCL) system delivering faster acting insulin aspart (FiASP) vs. insulin aspart in adults with type 1 diabetes. FiASP has a more rapid onset and shorter duration of insulin action, therefore may improve the responsive of a HCL system. There is limited data available regarding the use of FiASP in HCL systems. Participants will be assigned in random order either FiASP or insulin aspart delivery for a six week duration each via the A-HCL system (Stage 1 and Stage 2). Stage 1 and Stage 2 will be separated by two weeks, during which the insulin assigned for Stage 2 will be delivered in open-loop (OL). Two meal interventions (missed meal bolus and delayed meal bolus) will be conducted each during both Stage 1 and 2, incorporating a 40g carbohydrate-containing meal at home for dinner. For the final week of the study (Stage 3), participants will revert to the insulin that they were assigned to in Stage 1 without a wash-out period in OL. This study will consist of ~5 visits over approximately a period of ~17 weeks. All participants will be provided with study devices and receive education regarding their use. The HCL system has advanced closed-loop (CL) capability. It comprises a continuous glucose monitoring (CGM) device ie. glucose sensor with a small electrode placed under the skin to continuously measure interstitial glucose levels, coupled with an insulin pump containing a computerised automated insulin delivery algorithm. Glucose sensor information is transmitted to the insulin pump, and the dose of insulin is calculated by the algorithm and automatically delivered every 5 minutes to account for basal insulin requirements. Patient-initiated bolus insulin doses are still required for meals. Twenty-four participants are planned to undertake the study at one clinical site. All procedures involving study participants will be undertaken by study doctors and research nurses. Participants will receive regular text message and phone call reminders during each stage of the study to ensure adherence.

Sponsors

Medtronic Diabetes
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Type 1 diabetes of >1 year duration Stable on insulin pump therapy for >3 months Proficient in carbohydrate counting Continuous glucose monitoring (CGM) sensor experience HbA1c <10.0%

Exclusion criteria

Pregnancy eGFR <40ml/min/1.73m2 History of diabetic ketoacidosis or severe hypoglycaemia in the last 3 months Diabetic gastroparesis

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 14, 2026